Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $16.50.

A number of analysts have recently commented on the company. Oppenheimer restated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Chardan Capital restated a “buy” rating and set a $20.00 price target on shares of Immuneering in a research note on Tuesday, May 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th.

Institutional Investors Weigh In On Immuneering

Several institutional investors have recently bought and sold shares of IMRX. Jane Street Group LLC purchased a new position in shares of Immuneering in the 1st quarter valued at $32,000. Geode Capital Management LLC increased its holdings in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after purchasing an additional 4,458 shares in the last quarter. XTX Topco Ltd acquired a new stake in Immuneering in the 2nd quarter valued at $90,000. Bridgeway Capital Management LLC raised its position in Immuneering by 57.9% in the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after purchasing an additional 35,000 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in shares of Immuneering during the second quarter worth about $215,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Price Performance

NASDAQ IMRX opened at $5.10 on Wednesday. The company has a market cap of $329.97 million, a P/E ratio of -4.36 and a beta of 0.41. Immuneering has a 12 month low of $2.90 and a 12 month high of $10.08. The company has a 50-day moving average of $4.86 and a 200-day moving average of $5.19.

Immuneering (NASDAQ:IMRX) last released its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. As a group, equities research analysts anticipate that Immuneering will post -1.12 EPS for the current year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.